Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?

被引:103
作者
Lazzari, Chiara [1 ]
Karachaliou, Niki [2 ,3 ]
Bulotta, Alessandra [1 ]
Vigano, Mariagrazia [1 ]
Mirabile, Aurora [1 ]
Brioschi, Elena [1 ]
Santarpia, Mariacarmela [4 ]
Gianni, Luca [1 ]
Rosell, Rafael [5 ,6 ,7 ]
Gregorc, Vanesa [1 ]
机构
[1] IRCCS San Raffaele, Dept Oncol, Div Expt Med, Via Olgettina 60, I-20132 Milan, Lombardia, Italy
[2] Univ Hosp Sagrat Cor, Inst Oncol Dr Rosell IOR, Barcelona, Spain
[3] Quiron Dexeus Univ Inst, Coyote Res Grp, Lab Mol Biol, Pangaea Oncol, Barcelona, Spain
[4] Univ Messina, Dept Human Pathol G Barresi, Med Oncol Unit, Messina, Italy
[5] Quiron Dexeus Univ Inst, Inst Oncol Dr Rosell IOR, Barcelona, Spain
[6] Inst Invest Ciencies Germans Trias & Pujol, Badalona, Spain
[7] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain
关键词
chemotherapy; immune checkpoint inhibitors; immune evasion; immune resistance; non-small cell lung cancer; PD-1; inhibitors; PD-L1; radiotherapy; PHASE-III TRIAL; CISPLATIN PLUS GEMCITABINE; RADIATION-THERAPY; PD-1; BLOCKADE; 1ST-LINE TREATMENT; TUMOR; NIVOLUMAB; DOCETAXEL; CARBOPLATIN; PEMBROLIZUMAB;
D O I
10.1177/1758835918762094
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immune checkpoint inhibitors have significantly improved overall survival with an acceptable safety profile in a substantial proportion of non-small cell lung cancer (NSCLC) patients. However, not all patients are sensitive to immune checkpoint blockade and, in some cases, programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitors accelerate tumor progression. Several combination strategies are under evaluation, including the concomitant or sequential evaluation of chemotherapy or radiotherapy with immunotherapy. The current review provides an overview on the molecular rationale for the investigation of combinatorial approaches with chemotherapy or radiotherapy. Moreover, the results of completed clinical studies will be reported.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 61 条
[1]   Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].
Antonia, S. J. ;
Villegas, A. ;
Daniel, D. ;
Vicente, D. ;
Murakami, S. ;
Hui, R. ;
Yokoi, T. ;
Chiappori, A. ;
Lee, K. H. ;
de Wit, M. ;
Cho, B. C. ;
Bourhaba, M. ;
Quantin, X. ;
Tokito, T. ;
Mekhail, T. ;
Planchard, D. ;
Kim, Y. -C. ;
Karapetis, C. S. ;
Hiret, S. ;
Ostoros, G. ;
Kubota, K. ;
Gray, J. E. ;
Paz-Ares, L. ;
de Castro Carpeno, J. ;
Wadsworth, C. ;
Melillo, G. ;
Jiang, H. ;
Huang, Y. ;
Dennis, P. A. ;
Ozguroglu, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929
[2]   Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data [J].
Auperin, A. ;
Le Chevalier, T. ;
Le Pechoux, C. ;
Pignon, J. P. ;
Tribodet, H. ;
Burdett, S. ;
Stewart, L. A. ;
Tierney, J. F. ;
Stephens, R. J. ;
Arriagada, R. ;
Higgins, J. P. ;
Johnson, D. H. ;
van Meerbeeck, J. ;
Parmar, M. K. B. ;
Souhami, R. L. ;
Bergman, B. ;
Dautzenberg, B. ;
Douillard, J. Y. ;
Dunant, A. ;
Endo, C. ;
Girling, D. J. ;
Imaizumi, M. ;
Kato, H. ;
Keller, S. M. ;
Kimura, H. ;
Knuuttila, A. ;
Kodama, K. ;
Komaki, R. ;
Kris, M. G. ;
Lad, T. ;
Mineo, T. ;
Park, J. H. ;
Piantadosi, S. ;
Pyrhonen, S. ;
Rosell, R. ;
Scagliotti, G. V. ;
Seymour, L. W. ;
Shepherd, F. A. ;
Spiro, S. G. ;
Strauss, G. M. ;
Sylvester, R. ;
Tada, H. ;
Tanaka, F. ;
Torri, V. ;
Wada, H. ;
Waller, D. ;
Xu, G. C. .
LANCET, 2010, 375 (9722) :1267-1277
[3]   Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer [J].
Auperin, Anne ;
Le Pechoux, Cecile ;
Rolland, Estelle ;
Curran, Walter J. ;
Furuse, Kiyoyuki ;
Fournel, Pierre ;
Belderbos, Jose ;
Clamon, Gerald ;
Ulutin, Hakki Cuneyt ;
Paulus, Rebecca ;
Yamanaka, Takeharu ;
Bozonnat, Marie-Cecile ;
Uitterhoeve, Apollonia ;
Wang, Xiaofei ;
Stewart, Lesley ;
Arriagada, Rodrigo ;
Burdett, Sarah ;
Pignon, Jean-Pierre .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) :2181-2190
[4]   Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].
Borghaei, H. ;
Paz-Ares, L. ;
Horn, L. ;
Spigel, D. R. ;
Steins, M. ;
Ready, N. E. ;
Chow, L. Q. ;
Vokes, E. E. ;
Felip, E. ;
Holgado, E. ;
Barlesi, F. ;
Kohlhaeufl, M. ;
Arrieta, O. ;
Burgio, M. A. ;
Fayette, J. ;
Lena, H. ;
Poddubskaya, E. ;
Gerber, D. E. ;
Gettinger, S. N. ;
Rudin, C. M. ;
Rizvi, N. ;
Crino, L. ;
Blumenschein, G. R. ;
Antonia, S. J. ;
Dorange, C. ;
Harbison, C. T. ;
Finckenstein, F. Graf ;
Brahmer, J. R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639
[5]   Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].
Brahmer, Julie ;
Reckamp, Karen L. ;
Baas, Paul ;
Crino, Lucio ;
Eberhardt, Wilfried E. E. ;
Poddubskaya, Elena ;
Antonia, Scott ;
Pluzanski, Adam ;
Vokes, Everett E. ;
Holgado, Esther ;
Waterhouse, David ;
Ready, Neal ;
Gainor, Justin ;
Aren Frontera, Osvaldo ;
Havel, Libor ;
Steins, Martin ;
Garassino, Marina C. ;
Aerts, Joachim G. ;
Domine, Manuel ;
Paz-Ares, Luis ;
Reck, Martin ;
Baudelet, Christine ;
Harbison, Christopher T. ;
Lestini, Brian ;
Spigel, David R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135
[6]   Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival [J].
Brown, Scott D. ;
Warren, Rene L. ;
Gibb, Ewan A. ;
Martin, Spencer D. ;
Spinelli, John J. ;
Nelson, Brad H. ;
Holt, Robert A. .
GENOME RESEARCH, 2014, 24 (05) :743-750
[7]   First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer [J].
Carbone, D. P. ;
Reck, M. ;
Paz-Ares, L. ;
Creelan, B. ;
Horn, L. ;
Steins, M. ;
Felip, E. ;
van den Heuvel, M. M. ;
Ciuleanu, T. -E. ;
Badin, F. ;
Ready, N. ;
Hiltermann, T. J. N. ;
Nair, S. ;
Juergens, R. ;
Peters, S. ;
Minenza, E. ;
Wrangle, J. M. ;
Rodriguez-Abreu, D. ;
Borghaei, H. ;
Blumenschein, G. R. ;
Villaruz, L. C. ;
Havel, L. ;
Krejci, J. ;
Corral Jaime, J. ;
Chang, H. ;
Geese, W. J. ;
Bhagavatheeswaran, P. ;
Chen, A. C. ;
Socinski, M. A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25) :2415-2426
[8]   Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 [J].
Champiat, Stephane ;
Dercle, Laurent ;
Ammari, Samy ;
Massard, Christophe ;
Hollebecque, Antoine ;
Postel-Vinay, Sophie ;
Chaput, Nathalie ;
Eggermont, Alexander ;
Marabelle, Aurelien ;
Soria, Jean-Charles ;
Ferte, Charles .
CLINICAL CANCER RESEARCH, 2017, 23 (08) :1920-1928
[9]   Role of Local Radiation Therapy in Cancer Immunotherapy [J].
Demaria, Sandra ;
Golden, Encouse B. ;
Formenti, Silvia C. .
JAMA ONCOLOGY, 2015, 1 (09) :1325-1332
[10]   Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]):: a randomised controlled trial [J].
Douillard, Jean-Yves ;
Rosell, Rafael ;
De Lena, Mario ;
Carpagnano, Francesco ;
Ramlau, Rodryg ;
Gonzales-Larriba, Jose Luis ;
Grodzki, Tornasz ;
Pereira, Jose Rodrigues ;
Le Groumellec, Alain ;
Lorusso, Vito ;
Clary, Claude ;
Torres, Antonio J. ;
Dahabreh, Jabrail ;
Souquet, Pierre-Jean ;
Astudillo, Julio ;
Fournel, Pierre ;
Artal-Cortes, Angel ;
Jassem, Jacek ;
Koubkova, Leona ;
His, Patricia ;
Riggi, Marcella ;
Hurteloup, Patrick .
LANCET ONCOLOGY, 2006, 7 (09) :719-727